Conditioning Regimen of Melphalan-busulfan and Fludarabine: a Randomized Study of Different Dose of Melphalan
About this study
Conditioning regimen with melphalan-busulfan and fludarabine (MBF) achieved low relapse rate in patients with acute myeloid leukemia (AML) and myelodysplasia syndrome (MDS). In our previous retrospective study, we demonstrated that melphalan dose at 100 or 140mg/m2 had similar incidence of relapse but it might had lower toxicities. In this prospective randomize study, we aim to compare the transplantation outcome in adult patients with AML/MDS receiving either MBF with 100 or 140 mg/m2 melphalan.
- Condition
- Toxicities, Survivorship
- Tested
- melphalan
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Who can join
- Age
- 18 to 55 years
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 7
- Minimum age: 18 years
- Maximum age: 55 years
- Study condition: Toxicities, Survivorship
- Patients with AML in first remission
- Patients with MDS with bone marrow blast \>5% but remain less than 20% before transplantation
- Donor available: HLA matched sibling donor, 9\~10/10 matched unrelated donor or haplo-identical donor
- Inform consent provided
Exclusion 2
- Patients with active infection (bacteria, fungal or viral)
- Patients with abnormal liver, renal and cardiac function
Where
2 sites, 2 recruiting
Rui Jin Hospital
Shanghai, Shanghai Municipality, China
Zhaxin Hospital, Go Broad Health Care
Shanghai, Shanghai Municipality, China
Contact
-
Chun Wang
86-13386259777 Wangchunsh@mefmail.com.cn
Potential match only. Final eligibility is determined by the study team.